Amendia Inc., a leading provider of innovative spinal technologies, announced today that it entered into a strategic venture with Promimic, a forward-thinking supplier of surface treatments for orthopaedic implants, based in Gothenburg, Sweden. The venture allows Amendia to develop Promimic’s signature HAnano Surface technology for use with Amendia’s progressive patient-focused spinal implants. The alliance is another of many milestones for Amendia in 2015 as the company rapidly bolsters their product line for scalable growth while simultaneously improving supplemental technology.
Amendia’s mission is to improve patient outcomes using advanced spinal implant technology. The venture with Promimic is another step forward in Amendia’s quest for continuous development of disruptive technology in the spinal implant industry. The venture supports Amendia’s efforts to provide orthopaedic surgeons and neurosurgeons with clinically-relevant breakthrough technology to best help patients.
“Our venture with Promimic is a crucial step in developing enhanced spinal implant technology and to positively impact surgical outcomes and patient care”, said Jeff Smith, Amendia’s CEO. He added, “Once cleared by the FDA, leading edge surface treatments like Promimic’s HAnano Surface will be the future of Amendia’s product lines and the industry, and we are happy to develop uses for HAnano Surface technology at our headquarters.”
Promimic’s HAnano Surface represents a new era of implant surfaces, based on bio-mimicking synthetic bone minerals. The unique HAnano Surface is only 20 nanometers thin and is proven to improve and accelerate osseointegration in over 20 pre-clinical studies. After FDA clearance, Amendia hopes that HAnano Surface will provide a complementary addition to their spinal implant line, designed to be paired with biologics and instrumentation that change the spinal surgery industry.
“We’re thrilled to partner with Amendia as they begin to develop ways to pair our innovative HAnano Surface with Amendia’s cutting edge spinal implant designs,” said Ulf Brogren, Promimic’s CEO. “Both companies are committed to improving patient care through disruptive innovation, and Amendia’s commitment to these values will allow us to help them change the patient experience one implant at a time.”
The HAnano Surface technology has not been approved by the FDA and it has not received FDA clearance for marketing in the U. S. spine industry.
ABOUT AMENDIA, INC.
Headquartered in a state of the art manufacturing facility in Marietta, Georgia, Amendia is a leading provider of innovative medical devices used during spinal surgical procedures. Founded in 2008, Amendia’s mission is to exceed surgeon and patient expectations by creating balanced solutions with disruptive technologies for medical devices paired with biologics and instrumentation. Amendia’s vertically-integrated strategy focuses on improving surgical outcomes and the lives of patients with spinal disorders.
ABOUT PROMIMIC AB
Promimic, based in Gothenburg, Sweden, develops and markets products within nano-materials for innovative surface treatments. Promimic has developed a process that makes it possible to modify all types of implant materials and geometries with a nanometer-thin surface of synthetic bone minerals; HAnano Surface. HAnano Surface is based on the substance hydroxyapatite (HA), which by size, shape, structure and chemistry mimics the living bone tissue. The surface has been shown to fasten and improve the anchoring of implants in bone. The innovative HAnano Surface is licensed to dental and orthopaedic implants companies. For more information about the company, please visit the web page: http://www.promimic.com.